Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission [Phase 2]
This clinical trial update describes a Phase 2 study of zanubrutinib-based maintenance therapy in patients with newly diagnosed diffuse Larg…
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
A prospective, multicenter observational study in China assessing the real-world effectiveness and safety of glofitamab in adults with relap…
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy [Phase 2]
A Phase 2 clinical trial is evaluating autologous hematopoietic stem cell boost after CAR-T therapy in patients with diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 study evaluating novel targeted drugs combined with the R-ICE regimen for relapsed or refractory diffuse large B-cell lymphoma; curr…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma
Clinical trial update from Ruijin Hospital outlines a mechanism investigation of R-CHOP alone or in combination with tucidinostat for treati…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） [Phase 2]
Phase 2 trial evaluating orelabrutinib plus R-CHOP for CD5-positive diffuse large B-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma [Phase 2]
Phase 2 trial update on zanubrutinib combined with CAR T-cell therapy for recurrent or refractory aggressive B-cell non-Hodgkin lymphomas an…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma [Phase 4]
Clinical trial update for consolidation with axicabtagene ciloleucel after first-line treatment in high-risk diffuse large B-cell lymphoma (…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) [Phase 2]
Phase 2 clinical trial evaluating Zilovertamab Vedotin in combination with cyclophosphamide, doxorubicin, prednisone plus rituximab or a rit…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse [Phase 2]
Phase 2 trial evaluating Golcadomide after CAR T-cell therapy in adults with relapsed/refractory aggressive diffuse large B-cell lymphoma an…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older [Phase 2]
A Phase 2 clinical trial update describes evaluating a combination of tafasitamab, lenalidomide, and rituximab in frontline diffuse large B-…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Leuko Labs, Inc. is conducting a pivotal study to validate a novel non-invasive system for detecting severe neutropenia. The trial covers Di…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy [Phase 1, Phase 2]
Update on a Phase 1/Phase 2 study of tazemetostat in newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma treated with chem…
-
CLINICAL_TRIALS research · 2024-10-03Clinical Trial Update: A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
An international non-interventional study sponsored by OWKIN to build a large multimodal oncology data resource (clinical, imaging, and omic…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement [Phase 2]
A Phase 2 trial protocol outlines molecular subtype-guided R-CHOP-MTX with optional zanubrutinib for newly diagnosed diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL [Phase 2]
A Phase 2 clinical trial is evaluating zanubrutinib plus lenalidomide as maintenance therapy in Diffuse Large B-Cell Lymphoma and is current…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms [Phase 1]
Phase 1 trial of CD19-targeted CAR T cells for refractory/relapsed CD19-positive B-cell neoplasms (ALL, mantle cell lymphoma, diffuse large …
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma [Phase 1]
Phase I clinical trial update for RC19D2 cell injection in recurrent or refractory diffuse large B-cell lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL [Phase 3]
A Phase III clinical trial evaluating high-dose rituximab with CHOP as first-line therapy for newly diagnosed advanced diffuse large B-cell …
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: A Real-World Study on Extranodal Lymphoma
A real-world study on extranodal lymphoma is registered at Ruijin Hospital and is not yet recruiting.
-
CLINICAL_TRIALS research · 2024-08-26Clinical Trial Update: Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas
A completed clinical trial evaluated blood markers of reproductive hormones to assess ovarian reserve in younger patients with newly diagnos…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
This clinical trial update from Adaptive Biotechnologies aims to optimize ctDNA-based minimal residual disease assessment in patients with f…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors [Phase 2]
A Phase 2 clinical trial update evaluating the combination of CAR T-cell therapy with glofitamab for relapsed/refractory diffuse large B-cel…
-
CLINICAL_TRIALS research · 2024-08-21Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update investigating CD19-targeted CAR T cells for relapsed or refractory large B-cell lymphoma, currently recruiting…
-
CLINICAL_TRIALS research · 2024-08-15Clinical Trial Update: A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating zanubrutinib in combination with polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory …